|
1
|
Greenlee RT, Hill-Harmon MB, Murray T and
Thun M: Cancer statistics, 2001. CA Cancer J Clin. 51:15–36. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
American Cancer Society Report. Cancer
Facts and Figures. 2015.http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015Accessed.
November 08–2015
|
|
3
|
Greenberg R: Does prostate cancer
represent more than one cancer? Prostate Cancer: Science and
Clinical Practice. Mydlo JH and Godec CJ: (San Diego, CA). Academic
Press. 29–34. 2003. View Article : Google Scholar
|
|
4
|
Gohiji K and Kitazawa S: Molecular
mechanism of prostate cancer invasion and metastasis. Prostate
Cancer: Science and Clinical Practice. Mydlo JH and Godec CJ: (San
Diego, CA). Academic Press. 11–27. 2003. View Article : Google Scholar
|
|
5
|
Gutman AB and Gutman EB: ‘Acid’
phosphatase occurring in serum of patients with metastasizing
carcinoma of the prostate gland. J Clin Invest. 17:473–478. 1938.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Heller JE: Prostatic acid phosphatase: Its
current clinical status. J Urol. 137:1091–1103. 1987.PubMed/NCBI
|
|
7
|
Bahnson RR and Catalona WJ: Adverse
implications of acid phosphatase levels in the upper range of
normal. J Urol. 137:427–430. 1987.PubMed/NCBI
|
|
8
|
Lowe FC and Trauzzi SJ: Prostatic acid
phosphatase in 1993. Its limited clinical utility. Urol Clin North
Am. 20:589–595. 1993.PubMed/NCBI
|
|
9
|
Burnett AL, Chan DW, Brendler CB and Walsh
PC: The value of serum enzymatic acid phosphatase in the staging of
localized prostate cancer. J Urol. 148:1832–1834. 1992.PubMed/NCBI
|
|
10
|
Ablin RJ, Soanes WA, Bronson P and
Witebsky E: Precipitating antigens of the normal human prostate. J
Reprod Fertil. 22:573–574. 1970. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang MC, Valenzuela LA, Murphy GP and Chu
TM: Purification of a human prostate specific antigen. Invest Urol.
17:159–163. 1979.PubMed/NCBI
|
|
12
|
Papsidero LD, Wang MC, Valenzuela LA,
Murphy GP and Chu TM: A prostate antigen in sera of prostatic
cancer patients. Cancer Res. 40:2428–2432. 1980.PubMed/NCBI
|
|
13
|
Robert M, Gibbs BF, Jacobson E and Gagnon
C: Characterization of prostate-specific antigen proteolytic
activity on its major physiological substrate, the sperm motility
inhibitor precursor/semenogelin I. Biochemistry. 36:3811–3819.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stamey TA, Yang N, Hay AR, McNeal JE,
Freiha FS and Redwine E: Prostate-specific antigen as a serum
marker for adenocarcinoma of the prostate. N Engl J Med.
317:909–916. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tchetgen MB and Oesterling JE: The role of
prostate-specific antigen in the evaluation of benign prostatic
hyperplasia. Urol Clin North Am. 22:333–344. 1995.PubMed/NCBI
|
|
16
|
Brawer MK, Chetner MP, Beatie J, Buchner
DM, Vessella RL and Lange PH: Screening for prostatic carcinoma
with prostate specific antigen. J Urol. 147:841–845.
1992.PubMed/NCBI
|
|
17
|
Crawford ED, DeAntoni EP, Etzioni R,
Schaefer VC, Olson RM and Ross CA: Serum prostate-specific antigen
and digital rectal examination for early detection of prostate
cancer in a national community-based program. The Prostate Cancer
Education Council. Urology. 46:863–869. 1993.
|
|
18
|
Mettlin C, Murphy GP, Lee F, Littrup PJ,
Chesley A, Babaian R, Badalament R, Kane RA and Mostofi FK: The
Investigators of the American Cancer Society-National Prostate
Cancer Detection Project: Characteristics of prostate cancers
detected in a multimodality early detection program. Cancer.
72:1701–1708. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Catalona WJ, Smith DS, Ratliff TL and
Basler JW: Detection of organ-confined prostate cancer is increased
through prostate-specific antigen-based screening. JAMA.
270:948–954. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Babaian RJ and Camps JL: The role of
prostate-specific antigen as part of the diagnostic triad and as a
guide when to perform a biopsy. Cancer. 68:2060–2063. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Oesterling JE, Brendler CB, Epstein JI,
Kimball AW Jr and Walsh PC: Correlation of clinical stage, serum
prostatic acid phosphatase and preoperative Gleason grade with
final pathological stage in 275 patients with clinically localized
adenocarcinoma of the prostate. J Urol. 138:92–98. 1987.PubMed/NCBI
|
|
22
|
Partin AW, Kattan MW, Subong EN, Walsh PC,
Wojno KJ, Oesterling JE, Scardino PT and Pearson JD: Combination of
prostate-specific antigen, clinical stage, and Gleason score to
predict pathological stage of localized prostate cancer. A
multi-institutional update. JAMA. 277:1445–1451. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Blute ML, Bergstralh EJ, Partin AW, Walsh
PC, Kattan MW, Scardino PT, Montie JE, Pearson JD, Slezak JM and
Zincke H: Validation of Partin tables for predicting pathological
stage of clinically localized prostate cancer. J Urol.
164:1591–1595. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Partin AW, Mangold LA, Lamm DM, Walsh PC,
Epstein JI and Pearson JD: Contemporary update of prostate cancer
staging nomograms (Partin Tables) for the new millennium. Urology.
58:843–848. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ellis DW, Leffers S, Davies JS and Ng AB:
Multiple immunoperoxidase markers in benign hyperplasia and
adenocarcinoma of the prostate. Am J Clin Pathol. 81:279–284.
1984.PubMed/NCBI
|
|
26
|
Partin AW, Carter HB, Chan DW, Epstein JI,
Oesterling JE, Rock RC, Weber JP and Walsh PC: Prostate specific
antigen in the staging of localized prostate cancer: Influence of
tumor differentiation, tumor volume and benign hyperplasia. J Urol.
143:747–752. 1990.PubMed/NCBI
|
|
27
|
Stattin P, Vickers AJ, Sjoberg DD,
Johansson R, Granfors T, Johansson M, Pettersson K, Scardino PT,
Hallmans G and Lilja H: Improving the specificity of screening for
lethal prostate cancer using prostate-specific antigen and a panel
of kallikrein markers: A nested case-control study. Eur Urol.
68:207–213. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yousef GM and Diamandis EP: The new human
tissue kallikrein gene family: Structure, function, and association
to disease. Endocr Rev. 22:184–204. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Catalona WJ, Smith DS, Wolfert RL, Wang
TJ, Rittenhouse HG, Ratliff TL and Nadler RB: Evaluation of
percentage of free serum prostate-specific antigen to improve
specificity of prostate cancer screening. JAMA. 274:1214–1220.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Partin AW, Catalona WJ, Finlay JA, Darte
C, Tindall DJ, Young CY, Klee GG, Chan DW, Rittenhouse HG, Wolfert
RL, et al: Use of human glandular kallikrein 2 for the detection of
prostate cancer: Preliminary analysis. Urology. 54:839–845. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Haese A, Becker C, Noldus J, Graefen M,
Huland E, Huland H and Lilja H: Human glandular kallikrein: 2 A
potential serum marker for predicting the organ confined versus non
organ confined growth of prostate cancer. J Urol. 163:1491–1497.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee SW, Hosokawa K, Kim S, Jeong OC, Lilja
H, Laurell T and Maeda M: Highly sensitive porpus
silicon(P-Si)-based Human Kallikrein 2 (hK2) immunoassap platform
toward accurate diagnosis of prostate cancer. Sens Basel.
15:11972–11987. 2015. View Article : Google Scholar
|
|
33
|
Yu H and Rohan T: Role of the insulin-like
growth factor family in cancer development and progression. J Natl
Cancer Inst. 92:1472–1489. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Djavan B, Bursa B, Seitz C, Soeregi G,
Remzi M, Basharkhah A, Wolfram R and Marberger M: Insulin-like
growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for
prostate cancer detection. Urology. 54:603–606. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shariat SF, Bergamaschi F, Adler HL,
Nguyen C, Kattan MW, Wheeler TM and Slawin KM: Correlation of
preoperative plasma IGF-I levels with pathologic parameters and
progression in patients undergoing radical prostatectomy. Urology.
56:423–429. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shariat SF, Lamb DJ, Kattan MW, Nguyen C,
Kim J, Beck J, Wheeler TM and Slawin KM: Association of
preoperative plasma levels of insulin-like growth factor I and
insulin-like growth factor binding proteins-2 and −3 with prostate
cancer invasion, progression, and metastasis. J Clin Oncol.
20:833–841. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Blobe GC, Schiemann WP and Lodish HF: Role
of transforming growth factor beta in human disease. N Engl J Med.
342:1350–1358. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Perry KT, Anthony CT and Steiner MS:
Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF
beta 3 in normal and malignant human prostate. Prostate.
33:133–140. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shariat SF, Shalev M, Menesses-Diaz A, Kim
IY, Kattan MW, Wheeler TM and Slawin KM: Preoperative plasma levels
of transforming growth factor beta(1) (TGF-beta(1)) strongly
predict progression in patients undergoing radical prostatectomy. J
Clin Oncol. 19:2856–2864. 2001.PubMed/NCBI
|
|
40
|
Adler HL, McCurdy MA, Kattan MW, Timme TL,
Scardino PT and Thompson TC: Elevated levels of circulating
interleukin-6 and transforming growth factor-beta1 in patients with
metastatic prostatic carcinoma. J Urol. 161:182–187. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Perry KT, Anthony CT, Case T and Steiner
MS: Transforming growth factor beta as a clinical biomarker for
prostate cancer. Urology. 49:151–155. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shariat SF, Kattan MW, Traxel E, Andrews
B, Zhu K, Wheeler TM and Slawin KM: Association of pre- and
postoperative plasma levels of transforming growth factor beta(1)
and interleukin 6 and its soluble receptor with prostate cancer
progression. Clin Cancer Res. 10:1992–1999. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Giri D, Ozen M and Ittmann M:
Interleukin-6 is an autocrine growth factor in human prostate
cancer. Am J Pathol. 159:2159–2165. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shariat SF, Andrews B, Kattan MW, Kim J,
Wheeler TM and Slawin KM: Plasma levels of interleukin-6 and its
soluble receptor are associated with prostate cancer progression
and metastasis. Urology. 58:1008–1015. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Seiden MV, Kantoff PW, Krithivas K,
Propert K, Bryant M, Haltom E, Gaynes L, Kaplan I, Bubley G, DeWolf
W, et al: Detection of circulating tumor cells in men with
localized prostate cancer. J Clin Oncol. 12:2634–2639.
1994.PubMed/NCBI
|
|
46
|
Shariat SF, Gottenger E, Nguyen C, Song W,
Kattan MW, Andenoro J, Wheeler TM, Spencer DM and Slawin KM:
Preoperative blood reverse transcriptase-PCR assays for
prostate-specific antigen and human glandular kallikrein for
prediction of prostate cancer progression after radical
prostatectomy. Cancer Res. 62:5974–5979. 2002.PubMed/NCBI
|
|
47
|
Gregorakis AK, Holmes EH and Murphy GP:
Prostate-specific membrane antigen: Current and future utility.
Semin Urol Oncol. 16:2–12. 1998.PubMed/NCBI
|
|
48
|
Millon R, Jacqmin D, Muller D, Guillot J,
Eber M and Abecassis J: Detection of prostate-specific antigen- or
prostate-specific membrane antigen-positive circulating cells in
prostatic cancer patients: Clinical implications. Eur Urol.
36:278–285. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Epstein JI, Carmichael M and Partin AW:
OA-519 (fatty acid synthase) as an independent predictor of
pathologic state in adenocarcinoma of the prostate. Urology.
45:81–86. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shurbaji MS, Kalbfleisch JH and Thurmond
TS: Immunohistochemical detection of a fatty acid synthase (OA-519)
as a predictor of progression of prostate cancer. Hum Pathol.
27:917–921. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Swinnen JV, Roskams T, Joniau S, Van
Poppel H, Oyen R, Baert L, Heyns W and Verhoeven G: Overexpression
of fatty acid synthase is an early and common event in the
development of prostate cancer. Int J Cancer. 98:19–22. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Dhir R, Vietmeier B, Arlotti J,
Acquafondata M, Landsittel D, Masterson R and Getzenberg RH: Early
identification of individuals with prostate cancer in negative
biopsies. J Urol. 171:1419–1423. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Bolduc S, Lacombe L, Naud A, Grégoire M,
Fradet Y and Tremblay RR: Urinary PSA: A potential useful marker
when serum PSA is between 2.5 ng/mL and 10 ng/mL. Can Urol Assoc J.
1:377–381. 2007.PubMed/NCBI
|
|
54
|
Woodson K, O'Reilly KJ, Hanson JC, Nelson
D, Walk EL and Tangrea JA: The usefulness of the detection of GSTP1
methylation in urine as a biomarker in the diagnosis of prostate
cancer. J Urol. 179:508–511; discussion 511–512. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sokoll LJ, Ellis W, Lange P, Noteboom J,
Elliott DJ, Deras IL, Blase A, Koo S, Sarno M, Rittenhouse H, et
al: A multicenter evaluation of the PCA3 molecular urine test:
Pre-analytical effects, analytical performance, and diagnostic
accuracy. Clin Chim Acta. 389:1–6. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Deras IL, Aubin SM, Blase A, Day JR, Koo
S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, et al:
PCA3: A molecular urine assay for predicting prostate biopsy
outcome. J Urol. 179:1587–1592. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Neves AF, Araújo TG, Biase WK, Meola J,
Alcântara TM, Freitas DG and Goulart LR: Combined analysis of
multiple mRNA markers by RT-PCR assay for prostate cancer
diagnosis. Clin Biochem. 41:1191–1198. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Tinzl M, Marberger M, Horvath S and Chypre
C: DD3PCA3 RNA analysis in urine - a new perspective for detecting
prostate cancer. Eur Urol. 46:182–186; discussion 187. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Nakanishi H, Groskopf J, Fritsche HA,
Bhadkamkar V, Blase A, Kumar SV, Davis JW, Troncoso P, Rittenhouse
H and Babaian RJ: PCA3 molecular urine assay correlates with
prostate cancer tumor volume: implication in selecting candidates
for active surveillance. J Urol. 179:1804–1810. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
van Gils MP, Hessels D, van Hooij O,
Jannink SA, Peelen WP, Hanssen SL, Witjes JA, Cornel EB, Karthaus
HF, Smits GA, et al: The time-resolved fluorescence-based PCA3 test
on urinary sediments after digital rectal examination; a Dutch
multicenter validation of the diagnostic performance. Clin Cancer
Res. 13:939–943. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
van Gils MP, Hessels D, van de
Hulsbergen-Kaa CA, Witjes JA, Jansen CF, Mulders PF, Rittenhouse HG
and Schalken JA: Detailed analysis of histopathological parameters
in radical prostatectomy specimens and PCA3 urine test results.
Prostate. 68:1215–1222. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Hessels D, Smit FP, Verhaegh GW, Witjes
JA, Cornel EB and Schalken JA: Detection of TMPRSS2-ERG fusion
transcripts and prostate cancer antigen 3 in urinary sediments may
improve diagnosis of prostate cancer. Clin Cancer Res.
13:5103–5108. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Laxman B, Morris DS, Yu J, Siddiqui J, Cao
J, Mehra R, Lonigro RJ, Tsodikov A, Wei JT, Tomlins SA, et al: A
first-generation multiplex biomarker analysis of urine for the
early detection of prostate cancer. Cancer Res. 68:645–649. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Landers KA, Burger MJ, Tebay MA, Purdie
DM, Scells B, Samaratunga H, Lavin MF and Gardiner RA: Use of
multiple biomarkers for a molecular diagnosis of prostate cancer.
Int J Cancer. 114:950–956. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Ronquist G and Nilsson BO: The Janus-faced
nature of prostasomes. Their pluripotency favours the normal
reproductive process and malignant prostate growth. Prostate Cancer
Prostatic Dis. 7:21–31. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Delves GH, Stewart AB, Cooper AJ and
Lwaleed BA: Prostasomes, angiogenesis, and tissue factor. Semin
Thromb Hemost. 33:75–79. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Babiker AA, Hamad OA, Sanchez J, Ronquist
G, Nilsson B and Ekdahl KN: Prothrombotic effect of prostasomes of
metastatic cell and seminal origin. Prostate. 67:378–388. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Chavarro JE, Stampfer MJ, Campos H, Kurth
T, Willett WC and Ma J: A prospective study of trans-fatty acid
levels in blood and risk of prostate cancer. Cancer Epidemiol
Biomarkers Prev. 17:95–101. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Chavarro JE, Stampfer MJ, Li H, Campos H,
Kurth T and Ma J: A prospective study of polyunsaturated fatty acid
levels in blood and prostate cancer risk. Cancer Epidemiol
Biomarkers Prev. 16:1364–1370. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Gann PH, Hennekens CH, Ma J, Longcope C
and Stampfer MJ: Prospective study of sex hormone levels and risk
of prostate cancer. J Natl Cancer Inst. 88:1118–1126. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Platz EA, Leitzmann MF, Rifai N, Kantoff
PW, Chen YC, Stampfer MJ, Willett WC and Giovannucci E: Sex steroid
hormones and the androgen receptor gene CAG repeat and subsequent
risk of prostate cancer in the prostate-specific antigen era.
Cancer Epidemiol Biomarkers Prev. 14:1262–1269. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Severi G, Morris HA, MacInnis RJ, English
DR, Tilley W, Hopper JL, Boyle P and Giles GG: Circulating steroid
hormones and the risk of prostate cancer. Cancer Epidemiol
Biomarkers Prev. 15:86–91. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Prensner JR, Zhao S, Erho N, Schipper M,
et al: RNA biomarkers associated with metastatic progression in
prostate cancer: A multi-institutional high-throughput analysis of
SChLAP1. Lancet Oncol. 15:1469–1480. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Øverbye A, Skotland T, Koehler CJ, Thiede
B, Seierstad T, Berge V, Sandvig K and Llorente A: Identification
of prostate cancer biomarkers in urinary exosomes. Oncotarget.
6:30357–30376. 2015.PubMed/NCBI
|
